- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07657182
A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction (Nerve-RESTORE℠)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
- Navn: Stacy Arnold
- Telefonnummer: (386) 462-6800
- E-mail: clinicalresearch@axogeninc.com
Undersøgelse Kontakt Backup
- Navn: Hayley Nicolosi
- Telefonnummer: (386) 462-6800
- E-mail: hnicolosi@axogeninc.com
Studiesteder
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46260
- Rekruttering
- OrthoIndy
-
Kontakt:
- Melanie Glover
- Telefonnummer: 317-802-2880
- E-mail: mglover@orthoindy.com
-
Ledende efterforsker:
- Brandon Smetana, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
Study Participant Criteria
- Be ≥ 18 years of age at the time of consent;
- Willing and able to comply with all aspects of the treatment and evaluation schedule over a 24-month duration;
Provide documented Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to initiation of any study procedures;
Injury/Repair Criteria for Each Nerve
Primary or secondary nerve injury repair with sural nerve autograft or Avance Nerve Graft for fully transected reconstruction of the following upper extremity mixed and/or motor nerve(s):
- Median nerve: proximal nerve stump within 20 cm from the center point of the thenar eminence and distal to the crease of the elbow;
- Anterior interosseous nerve;
- Median nerve recurrent motor branch;
- Radial nerve: proximal nerve stump within 20 cm of the center of the forearm (midpoint between the tip of the olecranon and the styloid process) and distal to the mid-humerus;
- Posterior interosseous nerve.
- Zone of injury of eligible nerve(s) resectable to healthy nerve both distally and proximally and within the anatomical regions of Inclusion Criterion #4;
- In study participants with multiple eligible nerve repairs, repair of all eligible nerves completed with the same study treatment, either Avance Nerve Graft or sural nerve autograft;
- Measured nerve gap(s) following resection > 25 mm;
- Nerve(s) repaired ≤ 120 days post injury;
- Undergo coaptation on both the proximal and distal portion of the nerve gap(s) per the USPI for Avance Nerve Graft and per standard of care for sural nerve autograft; and
- Either treatment method, Avance Nerve Graft or sural nerve autograft, is a viable option for all eligible nerve repair(s) (i.e., volume of injured nerve[s] does not exceed availability of sural nerve autograft for reconstruction, study participants are not treated with a combination of treatment types).
Exclusion Criteria:
Study Participant Criteria
- Currently enrolled in another clinical study that may interfere with treatment, assessment of recovery, or participation in this study;
- Deformities or injuries of the limb, hand, or digits that affect both the primary and secondary assessments for eligible nerve repair(s);
- History of neuropathy of any etiology, diabetic neuropathy or any other known neuropathy including compressive/traumatic neuropathies affecting the target limb;
- History of progressive neurodegenerative or autoimmune disorder affecting peripheral nerve or motor function (e.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease);
- History of chronic ischemic condition of the upper extremity;
- Expected use of medication during the study that is known to impact nerve regeneration or to cause peripheral neuropathy;
- Undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular systems;
Participant is unlikely to comply with all study requirements and standard medical care procedures for the duration of the study schedule;
Injury/Repair Criteria for Each Nerve
- Median nerve repairs where the ulnar nerve has been transected due to injury or repair;
- Repair(s) of a sensory-only proximal nerve stump;
- Incomplete nerve transections;
- Multilevel nerve injury pattern requiring two or more isolated reconstructions along the nerve pathway (for example, reconstruction of median nerve in forearm and recurrent motor branch resulting in repair pattern of graft to native nerve to graft to distal target);
- Inadequate soft tissue coverage or extensive soft tissue injury which will impair recovery assessment;
- Nerve avulsion injuries and nerve traction injuries resulting in rupture of the nerve;
- Replantation/amputation of the limb, hand, or digits involved in both the primary and secondary assessments for eligible nerve repair(s);
- Nerve repairs utilizing either end-to-side or side-to-side coaptation techniques;
- Nerve transfer, tendon transfer, or other concomitant treatment at the time of nerve repair that affects assessment of function of the innervated muscle organ;
- Use of coaptation devices that include metallic components or activated polymers and coaptations completed with fibrin glue only; and
- Injuries with vascular damage resulting in inadequate perfusion despite repair (i.e., both radial and ulnar arteries injured [one injured artery is allowed]).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Avance Nerve Graft
Study Treatment: Avance Nerve Graft repairs of mixed or motor nerves (> 25 mm gaps)
|
A commercially available, sterile, single-use peripheral nerve scaffold indicated for the treatment of functional deficits, manufactured from decellularized and sterilized extracellular matrix derived from human peripheral nerve tissue.
Andre navne:
|
|
Aktiv komparator: Sural nerve autograft
Comparator: Sural nerve autograft repairs of mixed or motor nerves (> 25 mm gaps)
|
A patient's own peripheral nerve tissue harvested in a secondary surgical procedure of the lower extremity where a functioning sural nerve is sacrificed for use in the reconstruction of a nerve defect.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recovery of motor function
Tidsramme: Assessed at 24 months
|
Medical Research Council Classification (MRCC) of motor recovery score.
This is an ordinal scale from M0-M5, with grade M0 meaning no contraction and M5 meaning full recovery in all muscles.
|
Assessed at 24 months
|
|
Recovery of sensory function
Tidsramme: Assessed at 24 months
|
Medical Research Council Classification (MRCC) of sensory recovery score.
This is an ordinal scale from S0-S4, with grade S0 meaning absence of sensibility in the autonomous area and S4 meaning complete recovery (2-point discrimination, 2-6 mm).
|
Assessed at 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Meaningful recovery (MR) of motor and sensory function
Tidsramme: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Medical Research Council Classification (MRCC) of motor recovery score.
Meaningful recovery is defined as ≥ M3 MRCC of motor recovery and ≥ S3 MRCC of sensory recovery.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
Treatment response (TR) of motor and sensory function
Tidsramme: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Medical Research Council Classification (MRCC) of motor recovery score.
Treatment response is defined as a 1-point increase in MRCC score from post-operative baseline.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
Time to MR of motor and sensory function
Tidsramme: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Time from surgery to meaningful recovery of motor function in all repairs and of sensory function in mixed nerve repairs.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
Time to TR of motor and sensory function
Tidsramme: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Time from surgery to treatment response of motor function in all repairs and of sensory function in mixed nerve repairs.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
QuickDASH upper extremity disability score
Tidsramme: Assessed at 24 months
|
The QuickDASH questionnaire (including Work and Sports/Performance Art modules if applicable) is a PROM questionnaire to measure physical functions and symptoms in participants with upper limb musculoskeletal disorders and will be used to assess the study participant's functional quality of life (QoL)as it pertains to the affected arm.
This 11-item questionnaire addresses arm-specific symptoms and disability during the preceding week and is used to estimate the participant's view of disability.
Each item is based on an ordinal scale from 1 to 5, where higher values are worse.
QuickDASH scores range from 0 to 100, with a score of 0 indicating no disability and a score of 100 representing the most severe disability.
|
Assessed at 24 months
|
|
Lower Extremity Functional Scale (LEFS) score
Tidsramme: Assessed at 24 months
|
The LEFS is a valid and reliable assessment for documenting function for individuals and groups with injury or disability to the lower extremity.
It is based on the World Health Organization's model of disability and handicap and is applicable to a wide variety of participants with lower extremity orthopedic conditions, including participants with a range of disability levels, conditions, diseases, treatments, and ages.
Applicable to sural nerve autograft group only.
The LEFS consists of 20 questions, with each activity rated from 0 (extremely difficult or unable) to 4 (no difficulty).
Scores range from 0 to 80, where higher scores indicate better lower limb function.
|
Assessed at 24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: R. Glenn Gaston, MD, OrthoCarolina Research Institute, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ANG-CP-013
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Perifer nerveskade
-
Mayo ClinicTilmelding efter invitationAnatomi af GSV for Rescue Peripheral IV AccessForenede Stater
-
Truway Health, Inc.Tilmelding efter invitationEvaluering af In-Vitro Cryo Terapeutiske Protokoller på Humane Celleprøver (TWH-CRYO-001) (CRYO-IVT)Cellular Injury and Post-Cryogenic Recovery | Kryogenisk cellulær stress | Kuldeinduceret cellulær skade | Termisk Skade Reaktion | Post-thaw levedygtighedsforringelse | Osmotisk Stressskade | Biomekanisk Skadesmodellering (In-Vitro) | Blunt Force Injuries to the Extremities (Cellular Injury Model) | Vævsskade... og andre forholdForenede Stater
-
Hospital Universitari Son DuretaEspen; This research prize was funded by Nestle Nutrition Institute and...AfsluttetModerat til alvorligt traume, som defineret af en | Injury Severity Score (ISS) > 12 point var inkluderet i undersøgelsen.Spanien
-
Cairo UniversityAfsluttetPostoperativ smerte | Stellat ganglieblok | Magnesiumsulfat | Lokalbedøvelse | Modificeret radikal mastektomi | Pectoral nervEgypten
Kliniske forsøg med Avance Nerve Graft
-
Başakşehir Çam & Sakura City HospitalUmraniye Education and Research Hospital; Namik Kemal University School... og andre samarbejdspartnereIkke rekrutterer endnu
-
Yale UniversityRekrutteringLændesmerter | Vertebrogent smertesyndrom | Basivertebralnerven AblationForenede Stater
-
Ege UniversityHealth Institutes of TurkeyRekrutteringOveraktiv blæresyndrom | Overaktiv blære (OAB) | Transkutan posterior tibial nervestimulering (TTNS)Kalkun
-
Johns Hopkins UniversityAfsluttetSlutstadie nyresygdom | Hæmolyse | Arteriovenøs graftForenede Stater
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulAfsluttetUrethral Forsnævring
-
Fundacion Clinica Valle del LiliAfsluttet
-
Centre Hospitalier Universitaire de Liege26K Center for Clinical ResearchRekrutteringGummi recessionBelgien, Frankrig
-
Groupe Hospitalier Paris Saint JosephRekruttering
-
Arizona Heart InstituteUkendtThorax aortaaneurismeForenede Stater
-
Siriraj HospitalAfsluttetPlexus brachialis skadeThailand